RT Journal Article
SR Electronic
T1 Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 205
OP 209
DO 10.21873/anticanres.15474
VO 42
IS 1
A1 TOYA, RYO
A1 WATAKABE, TAKAHIRO
A1 MURAKAMI, DAIZO
A1 MATSUYAMA, TOMOHIKO
A1 SAITO, TETSUO
A1 FUKUGAWA, YOSHIYUKI
A1 NISHIMOTO, KOHEI
A1 ORITA, YORIHISA
A1 OYA, NATSUO
YR 2022
UL http://ar.iiarjournals.org/content/42/1/205.abstract
AB Background/Aim: We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation. Patients and Methods: Twenty-five patients underwent TPF-CCRT without elective nodal irradiaion (ENI). After the RT of 40 Gy, five patients (20%) without tumor regression underwent surgery. Others underwent RT with a median total dose of 66 Gy. Results: Of the five patients who underwent surgery after the RT of 40 Gy, two showed residual carcinoma pathologically and the other three were confirmed to have complete pathological response to the treatment. The 5-year local control rate was 87%. No patients exhibited regional failure. No acute toxicities of grade 5 or late toxicities ≥grade 3 were observed. Conclusion: TPF-CCRT provides excellent tumor control with acceptable toxicities. CCRT while omitting ENI is a reasonable approach for T3 N0 glottic carcinoma without vocal cord fixation.